Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Valproic acid
Drug ID BADD_D02329
Description Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton.[A178051] It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into the anticonvulsant effects of khelline when he found that all of his samples, dissolved in valproic acid, exerted a similar degree of anticonvulsive activity. It first received approval on February 28, 1978 from the FDA under the trade name Depakene.[L6190] Since then, it has been investigated for neuroprotective, anti-manic, and anti-migraine effects. It is currently a compound of interest in the field of oncology for its anti-proliferative effects and is the subject of many clinical trials in a variety of cancer types.
Indications and Usage **Indicated** for:[Label] 1) Use as monotherapy or adjunctive therapy in the management of complex partial seizures and simple or complex absence seizures. 2) Adjunctive therapy in the management of multiple seizure types that include absence seizures. 3) Prophylaxis of migraine headaches. 4) Acute management of mania associated with bipolar disorder. **Off-label** uses include: 1) Maintenance therapy for bipolar disorder.[A177919] 2) Treatment for acute bipolar depression.[A177928,A177931,A177934] 3) Emergency treatment of status epilepticus.[A177955]
Marketing Status approved; investigational
ATC Code N03AG01
DrugBank ID DB00313
KEGG ID D00399
MeSH ID D014635
PubChem ID 3121
TTD Drug ID D03LGY
NDC Product Code 11014-0050; 17349-0005; 68925-0002; 17856-0675; 43353-107; 60432-621; 63739-253; 70518-0730; 10888-8132; 11014-0054; 68108-0203; 68094-701; 0615-8205; 60687-262; 72189-010; 0832-0310; 17856-0792; 0121-0675; 0527-5250; 23639-0003; 43353-085; 0121-4675; 62135-196; 63629-2454; 71930-057; 72189-267; 43353-279; 63629-7597; 68094-193; 49452-8092; 0121-1350; 68071-2702; 0591-4012; 66064-8001; 63739-086; 69452-150; 70518-0079; 50383-792
UNII 614OI1Z5WI
Synonyms Valproic Acid | 2-Propylpentanoic Acid | 2 Propylpentanoic Acid | Divalproex | Depakene | Convulsofin | Depakote | Dipropyl Acetate | Divalproex Sodium | Semisodium Valproate | Vupral | Valproic Acid, Sodium Salt (2:1) | Propylisopropylacetic Acid | Ergenyl | Magnesium Valproate | Valproate | Valproate Sodium | Sodium Valproate | Calcium Valproate | Valproate Calcium | Depakine
Chemical Information
Molecular Formula C8H16O2
CAS Registry Number 99-66-1
SMILES CCCC(CCC)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Language disorder19.19.01.006; 17.02.08.0150.004144%Not Available
Vascular malformation24.03.03.014; 03.07.03.004--Not Available
Peripheral venous disease24.04.02.0220.000100%Not Available
Sinus node dysfunction02.03.03.0170.000100%
Multiple organ dysfunction syndrome08.01.03.0570.000849%
Anal incontinence17.05.01.021; 07.01.06.0290.000150%
Frustration tolerance decreased19.04.02.0160.000769%Not Available
Speech sound disorder19.19.01.0070.000399%Not Available
Somatic symptom disorder19.24.01.0060.000150%Not Available
Adenoidal hypertrophy22.04.05.0150.000150%Not Available
Agraphia19.21.01.007; 17.02.03.0130.000100%Not Available
Amyotrophy15.05.05.010; 17.05.03.0140.000150%Not Available
Anisometropia06.02.04.0080.000300%Not Available
Astigmatism06.02.04.0090.001148%Not Available
Cafe au lait spots23.05.01.0150.000100%Not Available
Cerebellar haemorrhage17.08.01.046; 24.07.04.0230.000200%Not Available
Change in sustained attention19.21.02.0090.000100%Not Available
Conductive deafness04.02.01.0120.000349%Not Available
Confabulation19.10.03.0090.000100%Not Available
Cyanosis central02.11.04.005; 22.02.02.0120.000200%Not Available
Cyanosis neonatal22.11.02.003; 18.04.09.0060.000150%Not Available
Drowning08.04.01.014; 12.01.18.0030.000150%Not Available
Haemangioma of skin24.03.06.008; 23.10.01.013; 16.26.01.0130.000150%Not Available
Hypermetropia06.02.04.0100.000549%Not Available
IgA nephropathy20.05.01.016; 10.02.01.0630.000100%Not Available
Impulsive behaviour19.18.01.0010.000849%Not Available
Infantile spasms19.21.02.011; 17.12.03.0270.000300%Not Available
Kyphoscoliosis15.10.04.0070.000200%Not Available
Mesenteric vein thrombosis24.01.08.004; 07.15.02.0130.000100%Not Available
Neonatal respiratory distress syndrome22.11.02.010; 18.04.10.0030.000399%Not Available
The 26th Page    First    Pre   26 27 28 29 30    Next   Last    Total 31 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene